This company has shut down. Inozyme is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardInozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.
Inozyme has raised $60.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2023.
Inozyme's investors include RA Capital Management, New Enterprise Associates, Sanofi Ventures, Sofinnova Investments, Novo Holdings.
Inozyme is headquartered in Boston, United States.
Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.
Inozyme is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Inozyme — Funding & Investors." VCBacked, July 27, 2023, https://www.vcbacked.co/company/inozyme. Accessed August 7, 2026.
VCBacked. (2023). Inozyme — Funding & Investors. Retrieved August 7, 2026, from https://www.vcbacked.co/company/inozyme
{{cite web |title=Inozyme — Funding & Investors |url=https://www.vcbacked.co/company/inozyme |website=VCBacked |access-date=August 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated